Imlygic
What Imlygic is used for
Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Advanced therapy: a gene, cell or tissue-engineered medicine.
Key facts
- Brand
- Imlygic
- Active substance
- talimogene laherparepvec
- Disease area
- Melanoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX51
- Marketing authorisation holder
- Amgen Europe B.V.
- Authorised in the EU since
- 2015
Official information
In the USA
Same active substance: Imlygic
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imlygic used for?
Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
What is the active substance in Imlygic?
Imlygic contains talimogene laherparepvec.
Who makes Imlygic?
The EU marketing authorisation holder is Amgen Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU